Authors
Loading...
CRISPR-Cas9 knockout reveals that smarcc1 loss impairs differentiation in asxl1-mutant hematopoietic cells, suggesting novel therapeutic targets.
Mineo Kurokawa (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: